AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04353817 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to ELX/TEZ/IVA)
Description: Placebo matched to ELX/TEZ/IVA for oral administration once daily (qd) in the morning.
Study NCT04353817 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to IVA)
Description: Placebo matched to IVA for oral administration qd in the evening.
Study NCT03849768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10296
Description: Drug: HS-10296 110 mg/55 mg + placebo The initial dose of HS-10296 110 mg once daily can be reduced to 55 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT03849768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Drug: Gefitinib 250 mg + placebo The initial dose of Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT06382571 — intervention group
Intervention type: DRUG
Intervention: Renin-Angiotensin System Inhibitor
Study NCT03344406 — intervention group
Intervention type: OTHER
Intervention: Telephonic interviews
Description: Qualitative concept elicitation telephone interviews will be conducted in subjects with asthma.
Study NCT03344406 — intervention group
Intervention type: OTHER
Intervention: E-RS: COPD
Description: E-RS questionnaire will directly measure respiratory symptom severity.
Study NCT03344406 — intervention group
Intervention type: OTHER
Intervention: Supplemental asthma items
Description: Supplemental asthma items will include one question on wheeze and an item on breathlessness with activities to evaluate shortness of breath associated with strenuous activities.
Study NCT03344406 — intervention group
Intervention type: OTHER
Intervention: Daily diary
Description: Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
Study NCT03344406 — intervention group
Intervention type: OTHER
Intervention: Sociodemographic questionnaire
Description: Sociodemographic questionnaire will capture subject's demographic characteristics, including age, gender, and the highest level of educational attainment.
Study NCT03344406 — intervention group
Intervention type: OTHER
Intervention: Clinical questionnaire
Description: Clinical questionnaire will capture subject's clinical characteristics including the number of asthma exacerbations in the past 12 months, absenteeism due to asthma in the past month, and the presence of comorbid conditions.
Study NCT03886597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Table Olives
Description: At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 60 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 5 minutes to ingest 60 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
Study NCT03886597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Table Olives
Description: At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 120 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 10 minutes to ingest 120 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
Study NCT03886597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Table Olives
Description: All the subjects will perform two experimental sessions of 30 days with 15 days of washout periods within experimental periods. In one experimental session subjects will ingest table olives and in the other session they will act as their own controls following their normal dietary habits. During all the experiment participants will avoid the consumption of products rich in phenolic and triterpenic compounds. Subjects will include the dose of 60 table olives within their normal dietary habits. Consequently, the olives will be consumed two times daily within each main meal; 30 olives before lunch and 30 olives before dinner. Blood samples will be collected at baseline and 15 and 30 days of each experimental session. Tolerability variables and blood pressure will also be measured.
Study NCT03599622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study NCT03599622 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT02026245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Data gloves to perform movements
Description: Using the electronic data gloves to perform a set routine of movements:~* 5DT 'dataglove 14 Ultra' Electronic glove (commercially available)~* New 'Tyndall/UU' developmental dataglove
Study NCT01395511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Tool : Acupuncture Seirin SJ 0.16 \* 40 (mm) / SJ 0.18 \* 50 (mm) L-type needles were used for the study.~Made from stainless steel needle SEIRIN JAPAN
Study NCT02136771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3, producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
Study NCT02136771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03159078 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Polymyxin B
Description: Comparison of Poly B monotherapy vs Polymyxin B plus carbapenem in MDR infections
Study NCT03159078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymyxin B
Description: Comparison of Poly B monotherapy vs Polymyxin B plus carbapenem in MDR infections
Study NCT02319863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatectomy (conventional method)
Description: A Simple Technique of Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy
Study NCT02319863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatectomy (rapid ligating)
Study NCT02562092 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reducing Risk Behavior
Description: A small survey will be conducted to identify risk factors and assess demographics. Participants will receive psychological support and counseling on reducing risk behavior for one year.
Study NCT02562092 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Support and Guidance
Description: A small survey will be conducted to identify risk factors and assess demographics. Participants with a positive HIV test will receive standard HIV care, support, and guidance from a psychologist and case manager including an assessment of basic needs (food, clothing, shelter), and counseling on risk taking behaviors for one year.
Study NCT00994799 — intervention group
Intervention type: DRUG
Intervention: ranibizumab
Description: 10mg/ml intravitreal injection
Study NCT00994799 — intervention group
Intervention type: RADIATION
Intervention: macular grid-pattern laser
Description: macular grid-pattern laser therapy
Study NCT01915524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV9202
Description: Intradermal injection of CV9202
Study NCT01915524 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: local radiation
Description: Radiotherapy will be administered in 4 daily fractions of 5 GY each to be administered within one week
Study NCT02802644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin is indicated to control hyperglycemia in type 2 diabetic patients.
Study NCT02802644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non DPP-4 Inhibitor
Description: This group patients is permitted to take any other oral anti-hyperglycemic agents except sitagliptin.
Study NCT01621971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled milrinone
Description: After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled milirinone and intravenous placebo (0.9% normal saline 0.05 ml/kg) are administered
Study NCT01621971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous milrinone
Description: After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an intravenous bolus of milrinone (50 μg/kg) are administered
Study NCT01580176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous GlucoseMonitor
Description: The blood glucose and blood lactate levels will be taken continuously by the Continuous GlucoseMonitor and will be recorded twelve times.
Study NCT02925377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular warm-up
Description: The intervention group replaced their regular warm-up routine with seven neuromuscular warm-up exercises performed for 15 minutes prior to each practice session (3x/week) over a period of eleven weeks.
Study NCT02925377 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard warm-up
Description: Athletes in the control group followed their regular 15 minutes warm-up routine provided by the team coaches.
Study NCT01069315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of fluid lavage solution
Description: Comparison of castile soap solution vs. normal saline solution.
Study NCT01069315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of fluid lavage pressure
Description: Comparison of low pressure vs. high pressure.
Study NCT00458575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 2476
Description: Participant 1 will receive 5.6x100000; Participants 2, 3, 5, 6, and 7 will receive 6.0x10000; Participant 4 will receive 3.0x100000; and Participants 8 and 9 will receive 1.2x100000 of CNTO 2476 as a single dose of viable cells in phosphate buffered saline (PBS) in a total volume of 100 μL injected subretinally.
Study NCT04108780 — intervention group
Intervention type: DEVICE
Intervention: T-tube
Description: T shaped tube used as stent after CBD exploration
Study NCT00931827 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel IUS (Mirena, BAY86-5028)
Description: Patients under daily life treatment receiving Mirena according to local drug information.
Study NCT00931827 — intervention group
Intervention type: DRUG
Intervention: Implanon (Etonogestrel)
Description: Patients under daily life treatment receiving Implanon according to local drug information.
Study NCT01924637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: A single dose will be administered subcutaneously (under the skin) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days.
Study NCT01924637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: A single dose will be administered subcutaneously (under the skin)) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days.
Study NCT04651309 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transperineal Ultrasound
Description: The ultrasound examination will be conducted using the technique described by Hassan et al (2013). Briefly, transperineal ultrasound images are obtained by placing a covered transducer between the labia below the symphysis pubis. Small lateral movements of the probe are then made to align the ultrasound beam in a midsagittal orientation to include the whole cervical length after which the probe is rotated 90 degrees in order to measure the cervical dilatation. The probe is rotated up and down until the echogenic circle of the cervix is seen. Please note that this technique is widely used within the delivery room and that the ultrasound machine that will be used is frequently used within the delivery room.
Study NCT00027976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study NCT02507843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Oral Cholecalciferol(100000 IU) will be administered in Vitamin D group monthly for 6 months.
Study NCT02507843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in placebo group monthly for 6 months.
Study NCT04851418 — intervention group
Intervention type: DEVICE
Intervention: Possible NSTE-ACS
Description: As mentioned in the group description
Study NCT00997022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dose escalation:~Dose level 1: 200mg of sorafenib daily~Dose level 2: 200mg of sorafenib BID (twice daily)~Dose level 3: 200mg QAM (taken every morning) and 400mg QPM (taken every evening)~Dose level 4: 400mg BID (twice daily)
Study NCT04283474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG005-03
Description: 3 different concentrations (1%, 5%, 10%) of XG005-03 topical formulation
Study NCT04283474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical formulation
Study NCT05475457 — intervention group
Intervention type: BEHAVIORAL
Intervention: R3
Description: Training, consultation, and fidelity-monitoring to supervisors in the child welfare system to reinforce (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement.
Study NCT04257253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted exercise program
Description: Participants in this experimental intervention group will perform a combination of motor control and isolated lumbar extensor strenghtening exercises. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.
Study NCT04257253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General exercise program
Description: Participants in this active intervention group will perform a generalized exercise program comprising upper-body and lower-body and hip strengthening exercises, as well as flexibility. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.
Study NCT01846806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
Study NCT03174691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: A total of ten (10) blood samples (2ml/each) will be collected during the study.~Blood samples will be collected on the following days for subsequent analysis of LH, Estradiol, hCG, progesterone and 17-Hydroxyprogesterone.
Study NCT01631838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich fraction 400mg
Description: Tocovid Suprabio 200mg is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
Study NCT01631838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
Study NCT02764203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark Chocolate
Description: 50g dark chocolate consumed for a period of 2 weeks
Study NCT02764203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable devices
Description: Up to three wearable devices will be worn by the subject to measure parameters such as heart rate, blood pressure and number of steps
Study NCT00347321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dilatational Percutaneous tracheostomy
Description: Dilatational Percutaneous tracheostomy
Study NCT04080089 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Surgical treatment, drug therapy, remote cognitive training
Description: Surgical treatment：Children with OSAHS who had surgical indications and informed consent from the parents underwent tonsillectomy and adenoidectomy.~drug therapy：For children whose parents only agree to receive medical treatment, montelukast sodium tablets are given for 6 months to reduce the inflammatory response of adenoids, tonsils, etc.~remote cognitive training:For children whose parents did not agree to undergo surgery or medication, the cognitive function was evaluated at the time of enrollment, and cognitive training was performed. Individualized training programs were developed according to the cognitive assessment system, and cognitive function was evaluated again after one course of treatment.
Study NCT00027976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03043482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single VS-105/placebo to healthy
Description: In Part 1, single ascending doses of VS-105 or placebo will be administered to approximately 5 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo.
Study NCT02978885 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SPECT-CT imaging
Description: Injection of AxV-128 labeled with 99mTc followed by SPECT CT
Study NCT02978885 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AxV-128/Tc
Description: Injection of AxV-128 labeled with 99mTc
Study NCT02978885 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Whipple procedure
Description: A Whipple procedure - also known as a pancreaticoduodenectomy - is a complex operation to remove the head of the pancreas, the first part of the small intestine (duodenum), the gallbladder and the bile duct.~The Whipple procedure is used to treat tumors and other disorders of the pancreas, intestine and bile duct. It is the most often used surgery to treat pancreatic cancer that's confined to the head of the pancreas. After performing the Whipple procedure, your surgeon reconnects the remaining organs to allow you to digest food normally after surgery. Standard of care.
Study NCT02978885 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Major surgery
Description: Additional surgical procedure(s) that is clinically indicated. Standard of care.
Study NCT03286231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT imaging
Description: Contrast-enhanced CT imaging of the pelvis in prone and jackknife positions
Study NCT03217968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cefaly® Abortive Program device
Description: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS).
Study NCT01446250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally
Study NCT01446250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir
Description: BOC 800 mg (4 x 200 mg soft gel capsules) administered orally
Study NCT01446250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
Study NCT01446250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
Study NCT01446250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Study NCT01446250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Study NCT01273155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).
Study NCT03043482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple VS-105/placebo to healthy
Description: In Part 2, multiple ascending doses of VS 105 or placebo will be administered each morning over 7 consecutive days to approximately 3 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo..
Study NCT01273155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belinostat
Description: Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).